Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia.
about
Erythropoietin or darbepoetin for patients with cancerHemoglobin level at initiation of darbepoetin alfa: impact on need for transfusion and associated costs in chemotherapy-induced anemia treatment in EuropeEffects of erythropoiesis-stimulating agents on fatigue- and anaemia-related symptoms in cancer patients: systematic review and meta-analyses of published and unpublished dataDarbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trialPatterns of erythropoiesis-stimulating agent use for chemotherapy-induced anemia in lung cancer: results of a retrospective Hungarian real-life clinical data analysis.Erythropoietin contrastingly affects bacterial infection and experimental colitis by inhibiting nuclear factor-κB-inducible immune pathwaysOverview of supportive care in patients receiving chemotherapy: antiemetics, pain management, anemia, and neutropenia.Post-diagnosis hemoglobin change associates with overall survival of multiple malignancies - results from a 14-year hospital-based cohort of lung, breast, colorectal, and liver cancers.Epoetin beta for the treatment of chemotherapy-induced anemia: an update.Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer.Contrasting effect of recombinant human erythropoietin on breast cancer cell response to cisplatin induced cytotoxicityOnco-nephrology: an appraisal of the cancer and chronic kidney disease links.Prevalence and management of anaemia in patients with non-myeloid cancer undergoing systemic therapy: a Spanish survey.Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trialErythropoiesis-stimulating agents in patients with cancer: update on safety issues.Efficacy and safety of darbepoetin alfa initiated at hemoglobin ≤10 g/dL in patients with stage IV cancer and chemotherapy-induced anemia.Darbepoetin alfa in anemia of myelodysplastic syndromes: present and beyond.Erythropoiesis-stimulating agents for anemic patients with cancer.Management of anemia in cancer patients.Hematologic outcomes and blood utilization in cancer patients with chemotherapy-induced anemia (CIA) pre- and post-national coverage determination (NCD): results from a multicenter chart review.Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia - systematic review and meta-analysis of randomised controlled trials.Darbepoetin alfa in the treatment of anemia in cancer patients undergoing chemotherapy.Reporting of meta-analyses of randomized controlled trials with a focus on drug safety: an empirical assessment.Prognostic impact of the combination of erythropoiesis-stimulating agents to cancer treatment: literature review.Fighting insomnia and battling lethargy: the yin and yang of palliative care.Pharmacovigilance in practice: erythropoiesis-stimulating agents.The Safety of Erythropoiesis-Stimulating Agents for the Treatment of Anemia Resulting from Chronic Kidney Disease.An overview on safety issues related to erythropoiesis-stimulating agents for the treatment of anaemia in patients with chronic kidney disease.Erythropoiesis-stimulating agents for the treatment of chemotherapy-induced anemia: comparisons from real-world clinical experience.Hemoglobin levels and quality of life in patients with symptomatic chemotherapy-induced anemia: the eAQUA study.Two faces for Janus: recombinant human erythropoiesis-stimulating agents and cancer mortality.Impact of erythropoiesis-stimulating agents on red blood cell transfusion in Korea.Blood conservation in neurosurgery: erythropoietin and autologous donation.
P2860
Q24202335-42A942EE-5353-4115-BEC8-A703A56F076EQ26865984-5ACE2A1A-75F5-466C-BADC-291C8BEDB7C3Q30803363-D0B4CEA4-ACE8-4DED-8F4E-1D02C0A01FD6Q33499897-400D42DB-CCAA-4C76-B5C6-AE840C7592BDQ33867969-21B882BD-F01F-4A79-A41B-E68989198ABDQ34544348-BD300CE9-4595-4005-A96A-CD46DAC5159BQ34635638-CD55E555-988E-4CFB-8DE4-0DD60EEC62E8Q34810071-A8C0A668-7033-4932-AFFF-65A160DE8438Q35168681-1566A332-618E-4F78-958A-03B0A0796289Q35858979-76C4E0EA-D814-42AC-839C-59C74F9D65E3Q36322416-04905E42-78CD-44A2-9E37-E573C45281F3Q36801561-202F4E1F-9978-4228-994E-7FE1C27602D3Q36875147-6DD05789-599A-4E52-BC6F-D1F1663F40E8Q37021210-2D0B51FB-B881-47C6-9F37-38210F23FAE2Q37564558-78B1E3BC-1A17-4348-83A9-D66F1AC2C5BAQ37577927-C9EF1399-F7A1-40A6-9DA5-6691AE3EFE20Q37702223-CA91CB35-03A0-48E5-83E5-690DBC15634FQ37810966-A6B56D27-D4DE-4607-88BF-346657420E44Q37861195-5A9F22C0-496E-4D7F-AEBF-3580F4F293B6Q37967407-3981983B-FFED-4FB7-94BC-B4C78CFEECCDQ38033247-42661E02-79E4-4776-B351-F602488FC167Q38056750-281F8D18-5CBD-4E72-8BFA-7400F54876B3Q38091030-15C30FAA-E3B3-4EC3-A495-4F0E4DB17D53Q38115153-E85C2A4F-B8B5-4C11-8577-287D542E6037Q38188834-64BC6963-CB07-4598-AC4F-9588494DBE31Q38217083-34F382BF-83A0-4CF5-AAA6-67E9177F1349Q38740871-CDF9E6E7-A3D8-4B3F-BECA-24DD17684EB1Q38826645-B43A68FA-2775-4056-9A9A-5BC21A6382BDQ39293869-E9D3DB2F-0CC1-488C-A7F9-24958CE44FF5Q40014607-58A97DE7-D443-4770-8E88-19C3C2244303Q42480000-B253FD8D-24A2-46A7-AE72-F8AB4FA0450CQ47582617-17711109-4549-42DF-9085-7B17AE5EAE77Q50457423-312B3A74-FEE9-4245-9EA6-61F6A2F9405B
P2860
Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia.
description
2009 nî lūn-bûn
@nan
2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Pooled analysis of individual ...... h chemotherapy-induced anemia.
@ast
Pooled analysis of individual ...... h chemotherapy-induced anemia.
@en
type
label
Pooled analysis of individual ...... h chemotherapy-induced anemia.
@ast
Pooled analysis of individual ...... h chemotherapy-induced anemia.
@en
prefLabel
Pooled analysis of individual ...... h chemotherapy-induced anemia.
@ast
Pooled analysis of individual ...... h chemotherapy-induced anemia.
@en
P2093
P921
P356
P1476
Pooled analysis of individual ...... h chemotherapy-induced anemia.
@en
P2093
Alex Fleishman
Anders Osterborg
David H Henry
Jeffrey Crawford
Johan Vansteenkiste
John A Glaspy
Ken Bridges
P304
P356
10.1200/JCO.2008.19.1130
P407
P50
P577
2009-04-20T00:00:00Z